Caterpillar Inc. (NYSE:CAT) is one of the stocks Jim Cramer commented on. Cramer mentioned the stock during the episode and commented: What else do we need so badly that we’ll pay anything for? Well, how about Caterpillar? We like their stuff. Turbines, GE Vernova. Hey, how about things that move other things? FedEx is good, any trucker. How about value-oriented companies like Walmart, Dollar General, Costco, Dollar Tree, TJX, they report tomorrow. All those companies make things and sell them cheaper tha ...

SOMERSET, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, March 10, 2026, to review fourth-quarter and full-year 2025 financial results. During the conference call and accompanying webcast, senior management will provide an overview of quarterly and full-year financial performance. Investors and other interested parties may access the live audio webcast via ...

Wall Street regulator allows intraday trading of tokenized WisdomTree money market fund | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]A screen displays the logo for WisdomTree following its debut on the floor of the New York Stock Exchange (NYSE) in New York City, U.S., November 7, 2022. REUTERS/Brendan McDermid [Purchase Licensing Rights, opens new tab]- Companies[Wisdomtree Inc]FollowWASHINGTON, Feb 23 (Reuters) - The U.S. Secu ...

Skip to main contentExclusive news, data and analytics for financial market professionalsLearn more aboutRefinitivBayer files lawsuit against Johnson & Johnson, Janssen BiotechFebruary 23, 20263:43 PM UTCUpdated agoBy ReutersThe 120 metres high Bayer Cross, logo of German pharmaceutical and chemical maker Bayer AG, consisting of 1710 LED glass bulbs is seen outside the industrial park "Chempark" of the chemical... Purchase Licensing Rights, opens new tab Read moreCompaniesBayer AGJanssen Biotech IncJohnson ...

Core Viewpoint - Arcellx's stock surged approximately 80% following Gilead Sciences' announcement to acquire the cancer-therapy developer for $7.8 billion in an all-cash deal, with a definitive buyout price set at $115 per share [1]. Deal Structure - Gilead will pay $115 per share in cash, plus a contingent value right (CVR) worth an additional $5 per share if Arcellx's lead therapy, anito-cel, achieves at least $6 billion in cumulative global net sales by the end of 2029 [1]. - The total offer represents a premium of about 87% over Arcellx's previous closing price, prompting immediate trading activity towards the buyout price [1]. - The transaction is structured as a tender offer followed by a second-step merger, already approved by both companies' boards [1]. Strategic Importance - Gilead is acquiring anitocabtagene autoleucel (anito-cel), a CAR-T therapy for relapsed or refractory multiple myeloma, which presents a significant commercial opportunity despite intense competition from established products like Johnson & Johnson's Carvykti [1]. - Analysts have previously noted supportive data for anito-cel's potential, with comparisons to Carvykti as the datasets have matured [1]. - The FDA is expected to make a decision on anito-cel by December 23, 2026, which positions the acquisition within a near-launch timeframe rather than a distant research phase [1]. Historical Context - Gilead and Arcellx have collaborated in cell therapy since 2022, making this acquisition a consolidation of a program that Gilead is already familiar with [1].

Today in Bloomberg Deals: Live events as an AI antidote, J&J explores orthopedics sale and Paramount gets early DOJ nod for Warner Bros. https://t.co/b2I3vf1l6n ...

Core Insights - The Honey Pot Company has appointed Janis Smith-Gomez as Chair of its Board of Directors, effective January 1, 2026, highlighting a strategic leadership change within the company [1][3] Company Overview - The Honey Pot Co. is a leading feminine care brand founded in 2012, focusing on plant-derived ingredients and clinically tested formulas [4] - The company offers a wide range of holistic wellness products across various categories, including feminine hygiene, menstrual care, personal care, and sexual wellness [4] - The Honey Pot Co. aims to educate and support consumers globally regarding menstrual health and vaginal wellness, with products available in over 33,000 stores in the U.S. [4] Leadership Background - Janis Smith-Gomez has extensive experience in commercial and marketing roles, having worked at Johnson & Johnson and other major consumer goods companies [2] - Her previous roles include Vice President of US Marketing for Johnson & Johnson's skin health and beauty portfolio and Vice President of Global Brand Experience for its Medical Devices division [2] - Smith-Gomez's educational background includes a B.A. and an M.B.A. from the University of Chicago [2] Strategic Vision - The leadership transition is expected to enhance the company's growth and brand development, aligning with its mission of promoting human health and wellness [3] - The Honey Pot Co. emphasizes a purpose-driven approach, aiming to empower women and lead conversations around feminine health through education [3]

Core Viewpoint - EyePoint, Inc. has appointed Michael Campbell as Chief Commercial Officer to lead the commercial strategy and launch readiness for DURAVYU, an investigational treatment for retinal diseases currently in Phase 3 development [1][2] Company Overview - EyePoint, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for serious retinal diseases, with its lead product candidate DURAVYU expected to provide significant commercial potential [8][9] - The company is headquartered in Watertown, Massachusetts, and has a commercial manufacturing facility in Northbridge, Massachusetts [9] Leadership Appointment - Michael Campbell brings over 30 years of commercial leadership experience, having successfully launched several ophthalmology products, including Lucentis and Xiidra [1][3][4] - His previous roles include Chief Commercial Officer at Opthea and Senior Vice President at Viatris Eye Care, where he led the launch of Tyrvaya [3][4] Product Development - DURAVYU is currently in Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), with topline data expected in mid-2026 [8][10] - The product is designed as a sustained delivery treatment combining vorolanib, a selective tyrosine kinase inhibitor, and is positioned to potentially be the first sustained release TKI to market [2][8] Commercial Strategy - The company aims to leverage Campbell's expertise to position DURAVYU for a successful U.S. launch, emphasizing a patient-centric approach and robust clinical data [2][8] - DURAVYU is expected to address both VEGF-mediated vascular leakage and IL-6 mediated inflammatory drivers of DME, enhancing its potential market impact [10]

Core Insights - Kenvue exceeded Wall Street estimates for its fourth-quarter results and announced a global workforce reduction as it moves towards a planned acquisition by Kimberly-Clark [1] Financial Performance - Kenvue's fourth-quarter net sales increased by 3.2% to $3.78 billion, surpassing analysts' consensus of $3.68 billion [1] - The self-care segment, which includes brands like Tylenol and Benadryl, reported a 1.5% increase in net sales to $1.59 billion, exceeding estimates of $1.52 billion [1] - The essential health unit, housing brands such as Listerine and Band-Aid, achieved net sales of $1.15 billion, a 6.1% year-over-year rise, compared to the average estimate of $1.12 billion [1] - Kenvue posted a quarterly adjusted profit of 27 cents per share, while analysts had estimated 22 cents per share [1] Workforce Reduction - Kenvue's board approved a plan to optimize its operating model, resulting in a net reduction of approximately 3.5% of its global workforce, which was about 22,000 employees last year [1] - The planned job cuts are expected to incur pre-tax restructuring expenses and other charges totaling around $250 million in 2026 [1] Acquisition Plans - Kimberly-Clark proposed to acquire Kenvue for over $40 billion to create a global consumer health company, with the merger expected to close in the second half of 2026 [1]

Core Viewpoint - The SPDR Portfolio S&P 500 Value ETF (SPYV) has outperformed the S&P 500 index over the past year, returning 13.81% compared to the S&P 500's 11.81%, but has significantly lagged behind growth stocks over the past five years [1]. Group 1: Performance Comparison - SPYV returned 13.81% over the past year, while the S&P 500 returned 11.81% and the SPDR Portfolio S&P 500 Growth ETF (SPYG) returned 12.46% [1]. - Over five years, SPYV delivered total returns of 233.53%, significantly lower than SPYG's 399.44% [1]. - Year-to-date, SPYV is up 3.84%, contrasting with SPYG's decline of 3.46%, indicating value's potential to outperform during growth stock downturns [1]. Group 2: Investment Characteristics - SPYV focuses on companies with reasonable valuations and steady cash flows, making it suitable for investors seeking stability and income [1]. - The fund has a dividend yield of 1.77% and a low expense ratio of 0.04%, which is beneficial for long-term after-tax returns [1]. - The portfolio includes established companies like Apple (16.7% allocation), Walmart, and Exxon Mobil, providing a mix of technology and defensive cash flows [1]. Group 3: Investment Strategy and Risks - Investing in SPYV involves accepting lower long-term growth potential in exchange for valuation discipline and income generation [1]. - The fund has a concentration risk, with the top ten holdings representing approximately 23% of its assets [1]. - SPYV is designed for investors prioritizing stability and dividends over maximum capital appreciation, requiring patience during growth rallies [1].